[ACHN] Achillion Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.38 Change: 0.39 (9.77%)
Ext. hours: Change: 0 (0%)

chart ACHN

Refresh chart

Strongest Trends Summary For ACHN

ACHN is in the long-term down -83% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Fundamental Ratios
Shares Outstanding EPS-0.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-9
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.83% ROE-27.14% ROI
Current Ratio19.64 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities138.96 M Cash From Investing Activities-148.58 M Cash From Operating Activities-17.32 M Gross Profit
Net Profit-19.26 M Operating Profit-19.4 M Total Assets279.42 M Total Current Assets255.58 M
Total Current Liabilities13.01 M Total Debt610 K Total Liabilities13.41 M Total Revenue
Technical Data
High 52 week5.15 Low 52 week2.65 Last close3.1 Last change1.31%
RSI20.21 Average true range0.12 Beta0.8 Volume2.41 M
Simple moving average 20 days-9.36% Simple moving average 50 days-12.63% Simple moving average 200 days-13.92%
Performance Data
Performance Week-1.27% Performance Month-10.92% Performance Quart-26.37% Performance Half6.9%
Performance Year-26.01% Performance Year-to-date7.64% Volatility daily2.03% Volatility weekly4.55%
Volatility monthly9.32% Volatility yearly32.3% Relative Volume236.65% Average Volume1.22 M
New High New Low


2019-09-19 06:19:42 | How Much Cash Is Left In The Bank For Achillion Pharmaceuticals, Inc. NASDAQ:ACHN?

2019-09-07 09:30:01 | Why Is Achillion ACHN Down 11.2% Since Last Earnings Report?

2019-08-29 17:00:00 | Achillion to Present at the Baird 2019 Global Healthcare Conference

2019-08-09 08:24:12 | Achillion ACHN Reports Wider Y/Y Loss in Q2, Revenues Nil

2019-08-08 07:30:00 | Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update

2019-07-26 17:29:00 | Why Achillion Pharmaceuticals Stock Flew Higher Again Today

2019-07-23 12:30:00 | Why Achillion Pharmaceuticals Stock Is Soaring Again Today

2019-07-22 16:30:00 | Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today

2019-07-22 15:41:50 | Why Achillion Pharmaceuticals Stock Jumped Today

2019-07-22 07:00:00 | Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

2019-07-17 06:00:00 | Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update

2019-07-10 09:23:57 | Does Achillion Pharmaceuticals, Inc. NASDAQ:ACHN Have A High Beta?

2019-07-04 08:35:12 | Alexion's Ultomiris Receives EU Approval for PNH in Adults

2019-06-28 08:45:12 | Alexion Receives FDA Approval for Label Expansion of Soliris

2019-06-26 18:29:56 | Here’s What Hedge Funds Think About Achillion Pharmaceuticals, Inc. ACHN

2019-06-21 11:05:03 | Alexion's sBLA for Ultomiris Gets Priority Review From FDA

2019-06-13 07:00:00 | Achillion to Present at the JMP Securities Life Sciences Conference

2019-06-10 07:00:00 | Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association

2019-06-08 09:30:01 | Why Is Achillion ACHN Down 1.4% Since Last Earnings Report?

2019-05-17 08:03:47 | The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

2019-05-17 07:00:00 | Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

2019-05-14 06:00:00 | Achillion Granted Twentieth Patent for Factor D Portfolio

2019-05-13 09:13:01 | Achillion ACHN Reports Wider-Than-Expected Loss in Q1

2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

2019-05-09 16:00:00 | What You Need to Know About Achillion Pharmaceuticals' Q1 Update

2019-05-09 10:19:41 | Achillion: 1Q Earnings Snapshot

2019-05-09 06:00:00 | Achillion Reports First Quarter 2019 Financial Results

2019-05-02 06:00:00 | Biotech Bets and a Goodbye from a Favorite Expert

2019-04-06 09:30:01 | Why Is Achillion ACHN Up 25.6% Since Last Earnings Report?

2019-04-04 10:23:02 | Achillion Meets Enrollment Target in Kidney Disease Studies

2019-04-03 12:50:00 | Why Achillion Pharmaceuticals Stock Is Jumping Today

2019-04-03 06:00:00 | Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy

2019-03-28 16:41:08 | Achillion Completes Enrollment in Rare Blood Disorder Study

2019-03-27 06:00:00 | Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial

2019-03-13 13:09:06 | Achillion Pharmaceuticals, Inc. NASDAQ:ACHN: Are Analysts Right About The Drop In Earnings?

2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4

2019-03-08 06:00:00 | Achillion to Present at the Barclays Global Healthcare Conference

2019-03-07 06:00:00 | Achillion Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-21 12:57:06 | Why a Connecticut pharma firm moved its C-suite to Blue Bell

2019-02-21 06:00:00 | Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market

2019-02-19 06:00:00 | Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference

2019-02-12 07:50:00 | Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-02-11 06:00:00 | Achillion Appoints Brian Di Donato as Chief Financial Officer

2019-02-04 12:45:05 | Alexion's ALXN Earnings Beat Estimates in Q4, Shares Up

2019-01-31 06:00:00 | Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

2019-01-29 11:10:04 | Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

2019-01-10 10:49:30 | Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December

2019-01-10 05:00:00 | Top Picks 2019- Achillian Pharmaceuticals ACHN

2019-01-03 07:36:09 | The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

2019-01-03 06:00:00 | Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors